Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.

Rousseau, Jean-Charles; Zhu, Yong; Miossec, Pierre; Vignon, E.; Sandell, Linda J.; Garnero, Patrick; Delmas, Pierre D.

doi:10.1016/j.joca.2004.02.004

Cited by 87 publications

(62 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Findings of several recent studies support the concept that soluble biomarkers can predict structural joint damage in rheumatoid arthritis (RA) (7)(8)(9)(10)(11)(12). These typically reflect different aspects of both synthesis and degradation of matrix components and include markers of bone formation and resorption, cartilage turnover and/or degradation, and synovial hyperplasia and/or inflammation.…”

mentioning

confidence: 79%

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis

Maksymowych¹,

Landewé²,

Conner‐Spady³

et al. 2007

Arthritis & Rheumatism

153

100

View full text Add to dashboard Cite

Objective. In prospective studies, only baseline radiographic damage has been identified as an independent predictor of radiographic progression in ankylosing spondylitis (AS). Several biomarkers have been identified as independent predictors of radiographic progression in rheumatoid arthritis, however, and these may be of use in AS. This study was undertaken to analyze serologic biomarkers as predictors of radiographic progression in AS.Methods. We measured a panel of biomarkers reflecting cartilage turnover and osteoclasis. These biomarkers were cartilage oligomeric matrix protein, human cartilage gp-39 (YKL-40), type II collagen epitopes detected by the C2C and C1,2C degradation assays and the CPII synthesis assay, aggrecan 846 epitope, osteoprotegerin, and matrix metalloproteinase 3 (MMP-3). The analysis was performed in a cohort of AS patients from the Netherlands, Belgium, and France enrolled in a longitudinal study, the Outcome Assessments in Ankylosing Spondylitis International Study. We examined 2-year radiographic progression data scored using the modified Stoke AS Spine Score (mSASSS).Results. Complete data were available on 97 patients. Only the biomarkers YKL-40 and MMP-3 showed weak to moderate univariate correlation with 2-year progression. After adjustment for sex, age, disease duration, C-reactive protein level, and baseline mSASSS, only MMP-3 was significantly associated with 2-year progression (␤ ‫؍‬ 0.29, P ‫؍‬ 0.004). Logistic regression analysis revealed MMP-3 (cutoff 68 ng/ml; odds ratio 9.4 [95% confidence interval 1.6-56]) and baseline mSASSS (cutoff 10 mSASSS units; odds ratio 18.6 [95% confidence interval 2.5-138]) as the only independent predictors of 2-year progression (cutoff 3 mSASSS units; model R 2 ‫؍‬ 50%). MMP-3 was primarily contributory in patients who already had substantial baseline damage (>10 mSASSS units).Conclusion. These results indicate that MMP-3 is a significant independent predictor of radiographic progression in patients with AS, particularly in those with preexisting radiographic damage.Ankylosing spondylitis (AS) is characterized by the presence of inflammation in the spine and the development of ankylosis in the facet joints and intervertebral discs, which leads to immobility and functional impairment. The degree and rate of progression of radiographic changes can be reliably assessed using a validated scoring method, the modified Stoke AS Spine Score (mSASSS), which records structural changes in

show abstract

mentioning

confidence: 79%

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis

Maksymowych¹,

Landewé²,

Conner‐Spady³

et al. 2007

Arthritis & Rheumatism

153

100

View full text Add to dashboard Cite

show abstract

“…A range of serological assessments have been developed to investigate some of the key structural proteins of the ECM (Table 3). 56,60,129,144,[196][197][198][199][200]217,274,276,278,311,314,[331][332][333][334][335][336][337][338][339][340][341][342][343][344][345][346][347] Measurement of these proteins may provide key information in clinical settings on the tissue turnover profile, and thereby assists in patient diagnosis, in identification of those patients in most need of treatment, and finally, in monitoring of clinical efficacy of interventions. These technologies may also be used in preclinical settings, in ex vivo and in vitro cultures, to determine the molecular mode of action in the assembly and maintenance of the matrix.…”

Section: 311mentioning

confidence: 99%

Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue DiseasesPossibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure

Karsdal

Nielsen²,

Sand³

et al. 2013

ASSAY and Drug Development Technologies

241

216

View full text Add to dashboard Cite

“…12 We have developed an enzyme-linked immuno sorbent assay for type IIA N-propeptide (PIIANP) and have shown that serum PIIANP levels are decreased in OA patients. 13 Recently, an assay against type II N-propeptide (total PIINP) has been developed with serum levels decreased in patients with rheumatoid arthritis (RA). 14 The C-terminal neoepitope generated by collagenase-mediated cleavage of the type II collagen triple helix (the ¾ fragment) can be detected by two assays: one (the C1,2C assay) recognizes type I and type II collagens on the basis of sequence homology, while the other (the C2C assay) recognizes only type II collagen.…”

Section: Markers Of Cartilage Metabolismmentioning

confidence: 99%

Biological markers in osteoarthritis

2007

View full text Add to dashboard Cite

Osteoarthritis (OA) is a progressive disorder characterized by destruction of articular cartilage and subchondral bone, and by synovial changes. The diagnosis of OA is generally based on clinical and radiographic changes, which occur fairly late during disease progression and have poor sensitivity for monitoring disease progression. Progression of joint damage is likely to result primarily from an imbalance between cartilage degradation and repair, so measuring markers of these processes would seem a promising approach to improve the prediction of disease progression at the individual level. Moreover, genetic markers might be useful predictors of prognosis. The lack of fully effective, chondroprotective medications has limited the use of such potential markers to monitor the effect of treatment for OA. Nevertheless, owing to their dynamic changes in response to treatment, biological markers might provide relevant information more rapidly than imaging techniques (such as radiography and MRI) can, and should contribute to our understanding of mechanisms that underlie the clinical efficacy of OA treatments. Most of the identified genes involved in OA encode signal-transduction proteins, which provide the potential for novel therapeutic approaches. In this Review, we will use the recently proposed BIPED (i.e. burden of disease, investigative, prognostic, efficacy of intervention and diagnostic) classification of OA markers to describe the potential usage of a given marker.

show abstract

Serum levels of type IIA procollagen amino terminal propeptide (PIIANP) are decreased in patients with knee osteoarthritis and rheumatoid arthritis.

Cited by 87 publications

References 38 publications

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis

Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis

Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue DiseasesPossibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure

Biological markers in osteoarthritis

Contact Info

Product

Resources

About